Psyllium Supplementation in Adolescents Improves Fat Distribution & Lipid Profile: A Randomized, Participant-Blinded, Placebo-Controlled, Crossover Trial

Liggins Institute, University of Auckland, Auckland, New Zealand.
PLoS ONE (Impact Factor: 3.23). 07/2012; 7(7):e41735. DOI: 10.1371/journal.pone.0041735
Source: PubMed


We aimed to assess the effects of psyllium supplementation on insulin sensitivity and other parameters of the metabolic syndrome in an at risk adolescent population.
This study encompassed a participant-blinded, randomized, placebo-controlled, crossover trial. Subjects were 47 healthy adolescent males aged 15-16 years, recruited from secondary schools in lower socio-economic areas with high rates of obesity. Participants received 6 g/day of psyllium or placebo for 6 weeks, with a two-week washout before crossing over. Fasting lipid profiles, ambulatory blood pressure, auxological data, body composition, activity levels, and three-day food records were collected at baseline and after each 6-week intervention. Insulin sensitivity was measured by the Matsuda method using glucose and insulin values from an oral glucose tolerance test.
45 subjects completed the study, and compliance was very high: 87% of participants took >80% of prescribed capsules. At baseline, 44% of subjects were overweight or obese. 28% had decreased insulin sensitivity, but none had impaired glucose tolerance. Fibre supplementation led to a 4% reduction in android fat to gynoid fat ratio (p = 0.019), as well as a 0.12 mmol/l (6%) reduction in LDL cholesterol (p = 0.042). No associated adverse events were recorded.
Dietary supplementation with 6 g/day of psyllium over 6 weeks improves fat distribution and lipid profile (parameters of the metabolic syndrome) in an at risk population of adolescent males.
Australian New Zealand Clinical Trials Registry ACTRN12609000888268.

Download full-text


Available from: José G B Derraik,
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite years of advising patients to alter their dietary and supplementary fiber intake, the evidence surrounding the use of fiber for functional bowel disease is limited. This paper outlines the organization of fiber types and highlights the importance of assessing the fermentation characteristics of each fiber type when choosing a suitable strategy for patients. Fiber undergoes partial or total fermentation in the distal small bowel and colon leading to the production of short-chain fatty acids and gas, thereby affecting gastrointestinal function and sensation. When fiber is recommended for functional bowel disease, use of a soluble supplement such as ispaghula/psyllium is best supported by the available evidence. Even when used judiciously, fiber can exacerbate abdominal distension, flatulence, constipation, and diarrhea.Am J Gastroenterol advance online publication, 2 April 2013; doi:10.1038/ajg.2013.63.
    The American Journal of Gastroenterology 04/2013; 108(5). DOI:10.1038/ajg.2013.63 · 10.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is recognized as a public health threat that is engulfing the nation and the world. Since it is associated with a number of adverse health consequences, losing weight is often needed. This can be accomplished through a variety of interventions, ranging from surgery, to prescribed diet and exercise plans, to consuming over-the-counter supplements available for weight loss. Most individuals would be delighted to find a relatively effortless way to lose weight in “weight-loss pills.” People are attracted by the prospect of over-the-counter diet pills in part due to ease of access. The present review examines the scientific evidence concerning various weight-loss agents that are available over the counter or in food stores. The review provides a starting point to make informed choices, as well as advice for incorporating healthy alternatives in the diet.
    Integrative Weight Management, 01/2014: pages 395-412; , ISBN: 978-1-4939-0547-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study investigated the LDL-cholesterol (LDL-C)-lowering effects of psyllium in Brazilian dyslipidaemic children and adolescents. A total of fifty-one individuals (6–19 years) with mild-to-moderate hypercholesterolaemia were evaluated by conducting a randomised, double-blind, placebo-controlled, parallel clinical trial. Over an 8-week trial period, the participants were randomly allocated to one of two groups (control: n 25 and psyllium: n 26) using a computer-generated random number sequence. Fasting blood samples, dietary records and anthropometric data were collected. Both groups were treated with the National Cholesterol Education Program Step 2 diet for 6 weeks before randomisation. After this run-in period, a daily supplement of 7·0 g psyllium was given to the intervention group, while an equivalent amount of cellulose was given to the control group. Statistically significant changes between the control and intervention groups over time were observed for total cholesterol (7·7 %; − 0·39 mmol/l; P = 0·003) and LDL-C (10·7 %; − 0·36 mmol/l; P = 0·01). None of the participants reported any aversion to the smell, taste, appearance or texture of psyllium. No serious adverse effects were reported during the study. In addition to causing a significant reduction in LDL-C concentrations, psyllium therapy was found to be both safe and acceptable for the treatment of hypercholesterolaemic children and adolescents.
    British Journal Of Nutrition 11/2014; 113(01):1-8. DOI:10.1017/S0007114514003419 · 3.45 Impact Factor
Show more